The présent invention lies in the technical field of antibody thérapies involving a mechanism of target-cell destruction by ADCC. It relates to purified antibody compositions, obtained by chromatographic fractionation of the various charge isoforms naturally présent in an antibody composition and combining one or more chromatographic fractions corresponding to the prédominant peak of the chromatogram, the resulting monoclonal antibody composition being enriched in said prédominant peak, said peak representing at least 85% of the chromatogram of the composition obtained, for use as a médicament.
